Sagimet posts updated investor presentation on NASH, acne, cancer pipeline

Sagimet Biosciences Inc.

Company furnished investor slide deck dated August 10, 2023; no financial results disclosed.
Presentation focuses on novel therapies targeting metabolic dysfunction for NASH, acne, and cancer.
No quantitative updates (e.g., clinical data, revenue, guidance) provided in filing or exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.